Radiopharmaceutical therapy of bone metastases with 89SrCl 2, 186Re-HEDP and 153Sm-EDTMP: A dosimetric study using Monte Carlo simulation

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 7, 2007, Pages 1031-1038

  Strigari, L ^a   Sciuto, R ^a   D'Andrea, M ^a   Pasqualoni, R ^a   Benassi, M ^a   Maini, C L ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Dose distribution; Monte Carlo simulation; Pain palliation

Indexed keywords

CHLORIDE SR 89; ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BONE; BONE METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; DOSE CALCULATION; DOSIMETRY; GEOMETRY; HISTOGRAM; MONTE CARLO METHOD; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SIMULATION; TRANSPORT KINETICS;

BONE NEOPLASMS; COMPUTER SIMULATION; ETIDRONIC ACID; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; STRONTIUM; TREATMENT OUTCOME;

EID: 34250354452     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0302-4     Document Type: Article

References (48)

1. Twicross RG, Fairfield S. Pain in advanced cancer. Pain 1982;14:303-10.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
3. Slatkin N. Cancer-related pain and its pharmacological management in the patient with bone metastasis. J Support Oncol 2006;4(2 Suppl 19):15-21.
4. Lewington VJ. Bone seeking radionuclides for therapy. J Nucl Med 2005;46:38S-47S.
5. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79-86.
6. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992;33:1316-23.
7. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, et al. Strontium-89 therapy for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22.
8. De Klerk JMH, Zonnenmberg BA, van het Ship AD, van Dijk A, Han SH, Quirijnen JM, et al. Dose escalation study of Re-186 HEDP in patients with metastatic prostate cancer. Eur J Nucl Med 1994;21:1113-20.
9. Maxon HR III, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC et al. Re-186(Sn)-HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166:501-7.
10. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153 EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-44.
11. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 1989;15:784-95.
12. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7(12):1926-31.
13. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J Nucl Med 1999;40:1947-66.
14. Bouchet LG, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within cortical bone. J Nucl Med 1999;40:2115-24.
15. Whitwell JR, Spiers FW. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol 1976;21:16-38.
16. Beddoe AH. Measurements of the microscopic structure of cortical bone. Phys Med Biol 1977;22:298-308.
17. Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med. 2000;41:189-212.
18. Jokisch DW, Patton PW, Inglis BA, Bouchet LG, Rajon DA, Rifkin J, et al. NMR microscopy of trabecular bone and its role in skeletal dosimetry. Health Phys 1998;75:584-96.
19. Nelson WR, Hirayama H, Rogers D. The EGS4 Code System. SLAC-265. Stanford, CA: Stanford Linear Accelerator Center; 1985.
20. Kawrakow I. Accurate condensed history Monte Carlo simulation of electron transport. EGSnrc, the new EGS4 version. Med Phys 2000;27:485-98.
21. Kawrakow I, Rogers DWO. The EGSnrc Code System: Monte Carlo simulation of electron and photon transport. Technical Report PIRS-701. Ottawa, Canada: National Research Council of Canada; 2000.
22. http://www.nndc.bnl.gov/nudat2/
23. ICRU. Tissue substitutes in radiation dosimetry and measurement, ICRU Report 44. Bethesda, MD: ICRU; 1989.
24. ICRU. Photon, electron, proton and neutron interaction data for body tissues, ICRU Report 46. Bethesda, MD:ICRU; 1992.
25. Bartlett ML, Webb M, Durrant S, Morton AJ, Allison R, Macfarlane DJ. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med Mol Imaging 2002;29:1470-7.
26. Li L, Liang Z, Deng H, Kuang A, Tan T, Luo S. Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J 2002;115(7):1096-8.
27. 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 2001;42:230-6.
28. Early JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, et al. Samarium-153 biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.
29. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP for bone pain due to skeletal metastases. J Nucl Med 1994;35:63-9.
30. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, et al. Human pharmacokinetic of samarium-153-EDTMP metastatic cancer. J Nucl Med 1989;30:1814-8.
31. Harbert JC. Nuclear medicine therapy. New York: Thieme Medical; 1987; p 216-20.
32. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, Mc Ewan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549-57.
33. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res 1985;104:S13-9.
34. Kutcher GJ, Burman C. Calculation of complication probability factors for nonuniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1991;21:123-35.
35. Lewington VJ, Mc Ewan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective randomized double-blind cross-over study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954-8.
36. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210-4.
37. 186 Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000;41:647-54.
38. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, et al. A dose-controlled study of 153-Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91.
39. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-81.
40. Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, et al. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ter 1998;149:43-7.
41. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-41.
42. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer. A randomized controlled trial. Semin Oncol 1993;20:38-43.
43. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006;39:35-41.
44. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906.
45. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001;66:101-9.
46. Maini CL, Sciuto R, Romano L, Bergomi S. Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. J Exp Clin Cancer Res 2003;22:71-4.
47. Samaratunga RC, Thomas SR, Hinnefeld JD, Von Kuster LC, Hyams DM, Moulton JS, et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. J Nucl Med 1995;36(2):336-50.
48. Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175-9.